Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.

Front Oncol · 2019 · PMC6536039 · PMID 31165040

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

CRT with weekly cisplatin in LA-HNSCC showed a trend favoring the cisplatin arm in all outcome parameters including LRC, PFS and OS in the p16-positive group ( NCT01216020 ) ( 110 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.